IQVIA Shares Drop 5% on Book-to-Bill Miss Despite Raised Profit Forecast, Q1 Beat
summarizeSummary
IQVIA Holdings reported better-than-expected first-quarter results, with adjusted EPS of $2.90 (vs. $2.82 consensus) and revenue of $4.15 billion (vs. $4.10 billion consensus). The company also raised its full-year 2026 adjusted earnings forecast to $12.65-$12.95 per share, up from $12.55-$12.85. However, shares dropped over 5% in premarket trading due to a disappointing R&D Solutions book-to-bill ratio of 1.04x, which missed analyst expectations. This forward-looking metric is overshadowing the otherwise solid financial performance and guidance raise, indicating investor concern about future growth despite current strength.
At the time of this announcement, IQV was trading at $151.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $27.3B. The 52-week trading range was $134.65 to $247.05. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.